Kuvatris Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Kuvatris Therapeutics Inc (PXMD) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
API endpoints for this dataset
Kuvatris Therapeutics Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Kuvatris Therapeutics Inc | - | - | - | Yes |
| Competitors combined (168) | ||||
| High-Confidence Competitors (2) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PXMD Stock Performance relative to its Competitors
PXMD Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Erasca Inc | 282.9% | Outperformed |
| 2 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 3 | Climb Bio Inc | 282.9% | Outperformed |
| 4 | Sellas Life Sciences Group Inc | 282.9% | Outperformed |
| 5 | Cypherpunk Technologies Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Kuvatris Therapeutics Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Kuvatris Therapeutics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Kuvatris Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Kuvatris Therapeutics Inc |
0.01 | - |
 Astrazeneca Plc |
288,001.56 | 58,739.00 |
 Vertex Pharmaceuticals Inc |
138,476.62 | 12,951.60 |
 Regeneron Pharmaceuticals Inc |
100,445.66 | 16,896.20 |
 Intra cellular Therapies Inc |
13,599.88 | 680.85 |
 Karuna Therapeutics Inc |
12,190.19 | 11.29 |
| SUBTOTAL | 739,078.41 | 110,974.18 |
Sign in to see all competitors of Kuvatris Therapeutics Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Kuvatris Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Kuvatris Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Kuvatris Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Harmony Biosciences | Company report | 85% |
| CureMark LLC | Company report | 85% |
| Yamo Pharmaceuticals | Company report | 85% |
| GW Pharmaceuticals | Company report | 85% |
Company report basis, confidence, active dates and source counts for Kuvatris Therapeutics Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Kuvatris Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Biomarin Pharmaceutical Inc | Reportable 100.00 % |
| Blueprint Medicines Corporation | Single Reportable Segment 100.00 % |
| Alkermes Plc | Single Reporting Segment 100.00 % |
| Rhythm Pharmaceuticals Inc | Single Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Kuvatris Therapeutics Inc .
Kuvatris Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Kuvatris Therapeutics Inc | 0 | - | -1,354,110 |
| Astrazeneca Plc | 288,002 | 706,847 | 123,141 |
| Vertex Pharmaceuticals Inc | 138,477 | 31,979,259 | 9,817,037 |
| Regeneron Pharmaceuticals Inc | 100,446 | 1,096,444 | 312,615 |
| Intra cellular Therapies Inc | 13,600 | 3,370,554 | -369,683 |
| Karuna Therapeutics Inc | 12,190 | 1,129,100 | -43,368,000 |
| PEERS TOTAL | 739,078 | 899,173 | 70,781 |
Sign in to see all peers for Kuvatris Therapeutics Inc .
Kuvatris Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Vertex Pharmaceuticals Inc | United States 63.04 % |
| Newmarket Corporation | United States 40.32 % |
| Xoma Royalty Corporation | CH 54.36 % |
| Adc Therapeutics Sa | United States 96.73 % |
| Durect Corp | Europe 72.48 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Kuvatris Therapeutics Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 490 companies in Kuvatris Therapeutics Inc's industry classification, broader than the peer set above. Market cap in millions of $.Kuvatris Therapeutics Inc ranks #0 of 490 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 995, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,278,652 | 24.03 % |
| 2 | Johnson and Johnson | 691,817 | 13.00 % |
| 3 | Abbvie Inc | 521,524 | 9.80 % |
| 4 | Merck and Co Inc | 362,966 | 6.82 % |
| 5 | Novartis Ag | 1,234 | 5.2% |
| 6 | Abbott Laboratories | 1,234 | 5.2% |
| 7 | Novo Nordisk A | 1,234 | 5.2% |
| 8 | Pfizer Inc | 1,234 | 5.2% |
| 9 | Astrazeneca Plc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Kuvatris Therapeutics Inc | 0 | 0.00 % |
Market cap and industry share for the rest of Kuvatris Therapeutics Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-11.
Kuvatris Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (447 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.3x | - |
| EV / EBITDA | - | 15.1x | - |
| P/B | 8.1x | 4.2x | +3.8x |
| Return on Equity | -6,479.84 % | industry aggregate | -6,490.18 % |
| Return on Invested Capital | -1,303.21 % | -9.73 % (avg) | -1,293.48 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Kuvatris Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 995 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Kuvatris Therapeutics Inc's dedicated Suppliers and Customers pages, not here.
Kuvatris Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 6,490.2 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (62.80 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-62.4% annualized).
Methodology: see Methodology: SWOT Analysis.
Kuvatris Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Kuvatris Therapeutics Inc | 0.97 | 1.39 | - |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Vertex Pharmaceuticals Inc | 1.30 | 2.83 | 0.06 |
| Regeneron Pharmaceuticals Inc | 0.58 | 3.56 | 0.06 |
| Intra cellular Therapies Inc | 2.40 | 6.78 | - |
| Karuna Therapeutics Inc | 6.61 | 31.17 | - |
Sign in to see all peers for Kuvatris Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Kuvatris Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Kuvatris Therapeutics Inc | Q3 2024 | - | - |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +11.8 % | -39.6 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +36.3 % | +33.5 % |
| Intra cellular Therapies Inc | Q4 2024 | +50.8 % | - |
| Karuna Therapeutics Inc | Q3 2023 | - | - |
| PEERS TOTAL | +12.3 % | +72.6 % |
Sign in to see all peers for Kuvatris Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Kuvatris Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Kuvatris Therapeutics Inc | Q3 2024 | - | - |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +26.8 % | -4.4 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +104.1 % | +49.1 % |
| Intra cellular Therapies Inc | Q4 2024 | - | - |
| Karuna Therapeutics Inc | Q3 2023 | - | +175.5 % |
Sign in to see all peers for Kuvatris Therapeutics Inc .
Kuvatris Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Kuvatris Therapeutics Inc | - | - | - |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Vertex Pharmaceuticals Inc | 14.16% | 16.63% | 20.08% |
| Regeneron Pharmaceuticals Inc | 11.50% | 13.00% | 15.07% |
| Intra cellular Therapies Inc | - | - | - |
| Karuna Therapeutics Inc | - | - | - |
Sign in to see all peers for Kuvatris Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Kuvatris Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Kuvatris Therapeutics Inc | - | - |
| Astrazeneca Plc | 28.19 | 4.90 |
| Vertex Pharmaceuticals Inc | 34.99 | 10.69 |
| Regeneron Pharmaceuticals Inc | 21.04 | 5.94 |
| Intra cellular Therapies Inc | - | 19.97 |
| Karuna Therapeutics Inc | - | 1,079.64 |
| PEERS AVERAGE | 84.74 | 6.66 |
Sign in to see all peers for Kuvatris Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.